Aytu BioPharma (NASDAQ:AYTU) Stock Crosses Above Fifty Day Moving Average – Time to Sell?

Aytu BioPharma Inc. (NASDAQ:AYTU)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.21 and traded as high as $2.40. Aytu BioPharma shares last traded at $2.30, with a volume of 43,533 shares.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Ascendiant Capital Markets raised their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Finally, Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aytu BioPharma currently has a consensus rating of “Hold” and an average target price of $10.75.

Aytu BioPharma Stock Performance

The firm has a market cap of $25.54 million, a PE ratio of -0.52 and a beta of 0.25. The business has a 50 day simple moving average of $2.21 and a two-hundred day simple moving average of $2.37. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27.

Aytu BioPharma (NASDAQ:AYTU) last issued its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). The company had revenue of $12.41 million for the quarter, compared to analysts’ expectations of $12.05 million. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. As a group, equities research analysts forecast that Aytu BioPharma Inc. will post -0.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aytu BioPharma

A number of hedge funds have recently added to or reduced their stakes in the stock. AWM Investment Company Inc. bought a new stake in shares of Aytu BioPharma during the second quarter valued at approximately $1,332,000. Diadema Partners LP grew its stake in Aytu BioPharma by 12.1% in the fourth quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock worth $795,000 after purchasing an additional 33,118 shares in the last quarter. Crown Advisors Management Inc. bought a new position in Aytu BioPharma in the second quarter worth approximately $430,000. Persistent Asset Partners Ltd increased its holdings in Aytu BioPharma by 27.2% during the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after purchasing an additional 16,963 shares during the period. Finally, Two Sigma Investments LP increased its holdings in Aytu BioPharma by 96.2% during the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after purchasing an additional 33,701 shares during the period. 33.49% of the stock is currently owned by institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.